BioCentury | Sep 25, 2020
Product Development

Flagship’s Valo takes stab at cloud-based R&D with $96.5M and longitudinal human data

Flagship Pioneering is putting AI-accelerated drug development to the test with Valo Health LLC, whose cloud computing platform is geared to guide everything from target discovery to clinical trial design. Through Valo, the blue chip...
BioCentury | Aug 4, 2014
Company News

Inform Genomics management update

Inform Genomics Inc. , Boston, Mass. Business: Diagnostic Hired: Carl de Moor as chief technology officer, formerly senior principal epidemiology and lead at the Epidemiology Center of Excellence at IMS Health Holdings Inc. WIR Staff Diagnostic...
BioCentury | Oct 21, 2013
Company News

Inform Genomics, Tesaro deal

...Tesaro will use Inform Genomics' bioinformatics and genomic platforms to evaluate the risk of chemotherapy-induced nausea and...
...regimens and standard antiemetic therapy without a neurokinin 1 (NK1) substance P receptor (TACR1) antagonist. Inform Genomics...
...to rolapitant from Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK, Miami, Fla.) (see BioCentury, Oct. 7). Inform Genomics Inc....
BioCentury | Oct 8, 2012
Clinical News

OnPART diagnostic data

...with OnPART, but declined to disclose details. Inform expects the test will be available 3Q14. Inform Genomics Inc....
BioCentury | Aug 13, 2012
Emerging Company Profile

Inform Genomics: SNPing side effects

...most risk for side effects to drugs for inflammatory bowel diseases. Companies and Institutions Mentioned Inform Genomics Inc....
...Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Sidebars Inform Genomics Inc....
BioCentury | Jul 16, 2012
Clinical News

OnPART: Preliminary data

...not require FDA approval. The company plans to conduct 1 more study prior to launch. Inform Genomics Inc....
BioCentury | Dec 5, 2011
Financial News

Inform Genomics completes venture financing

Inform Genomics Inc. , Boston, U.K. Business: Cancer, Inflammation Date completed: 12/1/11 Type: Venture financing Raised: $1 million Investors: Angel investors; company management Note: The company raised over $1 million in a seed financing. WIR Staff...
BioCentury | May 22, 2008
Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Genome-wide identification of transcription factor targets Computational analysis of gene expression profiles following transcription factor activation could be useful for predicting and identifying...
BioCentury | May 22, 2008
Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Genome-wide protein-protein interaction screen The protein-fragment complementation assay (PCA) could be useful for identifying protein-protein interaction networks associated with multiple diseases. PCA uses...
BioCentury | May 11, 2001
Top Story

Merck to acquire Rosetta

MRK will acquire informational genomics company RSTA in a stock transaction. The companies said the net equity value of the deal is $620 million. RSTA had $53.3 million in cash at March 31. Under the...
Items per page:
1 - 10 of 13
BioCentury | Sep 25, 2020
Product Development

Flagship’s Valo takes stab at cloud-based R&D with $96.5M and longitudinal human data

Flagship Pioneering is putting AI-accelerated drug development to the test with Valo Health LLC, whose cloud computing platform is geared to guide everything from target discovery to clinical trial design. Through Valo, the blue chip...
BioCentury | Aug 4, 2014
Company News

Inform Genomics management update

Inform Genomics Inc. , Boston, Mass. Business: Diagnostic Hired: Carl de Moor as chief technology officer, formerly senior principal epidemiology and lead at the Epidemiology Center of Excellence at IMS Health Holdings Inc. WIR Staff Diagnostic...
BioCentury | Oct 21, 2013
Company News

Inform Genomics, Tesaro deal

...Tesaro will use Inform Genomics' bioinformatics and genomic platforms to evaluate the risk of chemotherapy-induced nausea and...
...regimens and standard antiemetic therapy without a neurokinin 1 (NK1) substance P receptor (TACR1) antagonist. Inform Genomics...
...to rolapitant from Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK, Miami, Fla.) (see BioCentury, Oct. 7). Inform Genomics Inc....
BioCentury | Oct 8, 2012
Clinical News

OnPART diagnostic data

...with OnPART, but declined to disclose details. Inform expects the test will be available 3Q14. Inform Genomics Inc....
BioCentury | Aug 13, 2012
Emerging Company Profile

Inform Genomics: SNPing side effects

...most risk for side effects to drugs for inflammatory bowel diseases. Companies and Institutions Mentioned Inform Genomics Inc....
...Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Sidebars Inform Genomics Inc....
BioCentury | Jul 16, 2012
Clinical News

OnPART: Preliminary data

...not require FDA approval. The company plans to conduct 1 more study prior to launch. Inform Genomics Inc....
BioCentury | Dec 5, 2011
Financial News

Inform Genomics completes venture financing

Inform Genomics Inc. , Boston, U.K. Business: Cancer, Inflammation Date completed: 12/1/11 Type: Venture financing Raised: $1 million Investors: Angel investors; company management Note: The company raised over $1 million in a seed financing. WIR Staff...
BioCentury | May 22, 2008
Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Genome-wide identification of transcription factor targets Computational analysis of gene expression profiles following transcription factor activation could be useful for predicting and identifying...
BioCentury | May 22, 2008
Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Genome-wide protein-protein interaction screen The protein-fragment complementation assay (PCA) could be useful for identifying protein-protein interaction networks associated with multiple diseases. PCA uses...
BioCentury | May 11, 2001
Top Story

Merck to acquire Rosetta

MRK will acquire informational genomics company RSTA in a stock transaction. The companies said the net equity value of the deal is $620 million. RSTA had $53.3 million in cash at March 31. Under the...
Items per page:
1 - 10 of 13